NCIt definition : An injectable formulation of a monoclonal antibody directed against programmed cell
death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint
inhibitory and potential antineoplastic activities. Upon subcutaneous administration,
envafolimab binds to PD-L1, blocking its binding to and activation of its receptor
programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to
neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer
cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results
in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is
a negative regulator of the immune system that limits the expansion and survival of
CD8 T cells.;
UNII : ES1M06M6QH;
CAS number : 2102192-68-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2102192-68-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;